Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neoprobe makes second major investment in Israel:

This article was originally published in Clinica

Executive Summary

Neoprobe (US) is investing in XTL Biopharmaceuticals' (Israel) Trimera human monoclonal technology in what will be its second major deal in Israel (see Clinica No 672, p 15). Neoprobe has bought $1.5 million in XTL convertible debentures, providing it with 15% equity interest in the company with the option of taking a further 10%. It has also issued XTL with 125,000 shares of its common stock in exchange for worldwide licensing rights to its technology. XTL was founded on radiation chimera technology developed at the Weizmann Institute of Science. The company develops fully human monoclonal antibodies and provides a tool to model human diseases.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT087389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel